Xilio Therapeutics, Inc. (XLO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 748.98M |
| Enterprise Value | 618.4M |
| P/E Ratio | -6.1 |
| PEG Ratio | -0.03 |
| Price/Sales Ratio | 0.93 |
| Price/Book Ratio | 2.44 |
| Enterprise/Revenue | -1.09 |
| Enterprise/EBITDA | 3.41 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
Profitability
| Profit Margin | -0.34 |
| Operating Margin | -0.49 |
AD
Management Effectiveness
| Return On Assets | -0.14 |
| Return On Equity | -0.51 |
Income Statement
| Revenue | 43.77M |
| Revenue/Share | 3.3 |
| Gross Profit | 42.23M |
| EBITDA | -33.49M |
| Net Income | -35.04M |
| Diluted EPS | -4.19 |
Balance Sheet
| Total Cash | 136.04M |
| Total Cash/Share | 7.01 |
| Total Debt | 6.3M |
| Total Debt/Equity | 0.09 |
| Current Ratio | 4.25 |
| Book Value Per Share | 3.72 |
Price History
| 52-Week Change | -11.06 |
| 52-Week High | 12.74 |
| 52-Week Low | 6.47 |
| Moving Average 50 Days | 9.06 |
| Moving Average 200 Days | 8.67 |
Statistics
| Average Volume | 30,985 |
| Shares Outstanding | 6.58M |
| % Held by Institutions | 14.21 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:14 |
| Last Split Date | March 16, 2026 |
AD
